Gene therapy for ALS works by targeting the genetic mutations that cause motor neurons to degenerate, either silencing the faulty gene so it stops producing a toxic protein or editing the gene itself. The first gene-targeted ALS treatment, tofersen, received FDA approval based on its ability to reduce a key biomarker of nerve damage in people with a specific mutation, and several other gene-based approaches are now in clinical trials for different ALS-linked genes. The field is moving fast, but the biology is genuinely complex, and understanding what these therapies actually do, who they can help, and where the gaps remain gives a clearer picture than the headlines alone.
Why Genetics Matters in ALS
ALS has long been split into two rough categories: familial (inherited) and sporadic (no known family history). About 5 to 10 percent of cases are familial, with the rest classified as sporadic. But that distinction has gotten blurrier as researchers have found genetic mutations in people who have no affected relatives. In one German study of 302 patients with sporadic ALS, nearly 9 percent carried a mutation in the C9orf72 gene, a proportion higher than expected and a strong hint that genetic factors reach well beyond the “familial” label.1PubMed. Frequency of C9orf72 and SOD1 mutations in 302 sporadic ALS patients from three German ALS centers Another study found that over half of patients with C9orf72 mutations reported no family history of the disease.2Brain Communications. Clinical and genetic features of amyotrophic lateral sclerosis patients with C9orf72 mutations
The mutations that matter most for gene therapy today are concentrated in a handful of genes. SOD1, the first ALS gene ever identified, produces a protein that normally mops up harmful molecules inside cells. When SOD1 is mutated, it misfolds and clumps into toxic aggregates that poison motor neurons.3PubMed Central. Protein aggregation and therapeutic strategies in SOD1- and TDP-43- linked ALS C9orf72 is the most common known genetic cause of ALS, driven by a stretch of DNA that repeats itself far more times than it should. That repeat expansion produces toxic proteins that damage cells through several pathways.4PubMed Central. Phase Separation of Toxic Dipeptide Repeat Proteins Related to C9orf72 ALS/FTD FUS and TDP-43 round out the most-studied group, each contributing to ALS through proteins that behave badly when their genes carry mutations. The important point is that gene therapy is not a single treatment; it is a family of approaches, each designed around the specific mutation driving a person’s disease.
How Gene-Silencing Therapies Work
Most gene therapies currently in development or in use for ALS aim to silence a mutant gene rather than replace or repair it. The logic is straightforward: if a mutation causes the cell to produce a toxic protein, stop the cell from reading the instructions for that protein. There are three main tools being used to do this, each with different strengths.
Antisense oligonucleotides, or ASOs, are short synthetic strands of nucleic acid designed to bind to a specific RNA message inside a cell. When an ASO locks onto its target RNA, it recruits an enzyme that chops up the RNA, preventing the toxic protein from being made. This destruction happens in both the nucleus and the rest of the cell.5PubMed Central. RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus ASOs do not change the DNA itself; they intercept the message after it has been copied from the gene. Because ASOs break down over time, they require repeated doses, typically injected into the spinal fluid every few weeks or months.
A second approach uses viral vectors, usually a modified virus called AAV (adeno-associated virus), to deliver a tiny piece of genetic code into the cell. That code instructs the cell to produce an artificial microRNA, a small molecule that silences the target gene from within. In mouse models of SOD1-linked ALS, an AAV-delivered artificial microRNA cut human SOD1 RNA in the spinal cord by about half and by more than 80 percent in muscle and heart tissue.6PubMed Central. AAV delivered artificial microRNA extends survival and delays paralysis in an Amyotrophic Lateral Sclerosis mouse model In non-human primates, the same strategy safely silenced the SOD1 gene in motor neurons, supporting the idea that the approach could work in people.7PubMed. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques The advantage over ASOs is that a single dose of an AAV-based therapy can theoretically provide long-lasting gene silencing because the viral vector persists in the cell.
The third tool, CRISPR-Cas9 gene editing, takes a more permanent approach by cutting the mutant gene at the DNA level. In ALS mouse models carrying the SOD1 mutation, CRISPR-Cas9 delivered by AAV vectors disrupted the mutant gene in spinal cord cells, increased motor neuron survival, and extended lifespan by about 11 percent.8PubMed Central. CRISPR/Cas9 a genomic engineering technology for treatment in ALS mouse models Gene editing is the most direct of the three approaches, but it is also the hardest to reverse if something goes wrong, and it remains earlier in development for ALS than ASOs or AAV-delivered microRNAs.
Tofersen and SOD1-Linked ALS
Tofersen, sold as Qalsody, became the first gene-targeted therapy approved for ALS. It is an ASO injected into the spinal fluid that targets SOD1 RNA. The drug’s path to approval was unusual and worth understanding, because it reveals both what gene therapy can do right now and where the limits are.
In its main clinical trial, called VALOR, tofersen did not meet its primary goal. Patients who received the drug for 28 weeks did not show a statistically significant difference in functional decline compared to those on placebo.9PubMed. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS What the drug did achieve was a clear, measurable reduction in SOD1 protein in the spinal fluid and a drop in neurofilament light chain, a protein released when nerve cells are damaged. Neurofilament light chain, or NfL, has become an increasingly accepted marker of whether a treatment is slowing nerve damage, and the FDA’s decision to approve tofersen leaned heavily on that biomarker evidence.10PubMed Central. Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies
Longer-term data told a more encouraging story. When the trial’s open-label extension allowed all participants to receive tofersen, those who had started the drug earlier showed less functional decline than those whose treatment was delayed. At 52 weeks, the group that started early had declined by about 6 points on a standard ALS rating scale, compared to roughly 9.5 points for the delayed group.9PubMed. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS Real-world clinical data have reinforced the NfL findings, with significant drops in the biomarker observed across a broader range of SOD1 mutations than the trial alone studied.11PubMed. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice
The practical limitation is clear: tofersen helps only people with SOD1 mutations, who make up a small fraction of all ALS patients. SOD1 mutations account for roughly 2 percent of all ALS cases, or about 20 percent of familial cases. If you do not carry an SOD1 mutation, tofersen will not help. Genetic testing has therefore become a much more important early step in ALS diagnosis, since identifying a mutation can now directly change the treatment options available to you.
Therapies Targeting C9orf72 and FUS
Because C9orf72 repeat expansions are the most common genetic cause of ALS, several ASO programs are trying to do for C9orf72 what tofersen does for SOD1. The challenge is trickier. The C9orf72 gene has normal functions in the cell, so a good therapy needs to silence the toxic products of the expansion without wiping out the healthy protein. Early research showed that ASOs can selectively destroy the toxic RNA clumps that form inside cells without reducing overall C9orf72 protein levels.12PubMed Central. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration More recent work has refined this approach using stereopure oligonucleotides, chemically tuned ASOs that preferentially knock down the toxic RNA variant while preserving normal C9orf72 protein expression in preclinical models.13Nature Communications. Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models Several C9orf72-targeting ASOs are now in clinical trials.14PubMed Central. Antisense Oligonucleotides for the Study and Treatment of ALS
FUS mutations cause a particularly aggressive form of ALS, often striking younger people and progressing rapidly. An ASO called jacifusen (ION363) was developed to silence the FUS gene and has been tested in an open-label case series of FUS-ALS patients. The early results suggest the drug is safe and possibly effective, and a formal clinical trial is now ongoing.15PubMed Central. Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series A separate effort targets ATXN2, a gene whose intermediate-length expansions have been linked to sporadic ALS, broadening the potential reach of gene-based therapy beyond purely familial cases.14PubMed Central. Antisense Oligonucleotides for the Study and Treatment of ALS
Getting Treatments Into the Brain
The brain and spinal cord are surrounded by the blood-brain barrier, a tightly sealed network of blood vessels that keeps most drugs out. For ALS gene therapy, getting enough of the therapeutic material into motor neurons is one of the biggest engineering challenges. Tofersen sidesteps the barrier entirely by being injected directly into the spinal fluid through lumbar puncture, which is effective but invasive and requires periodic hospital visits.
AAV-based gene therapies face the same barrier problem but with different constraints. Among the many AAV types, AAV9 has emerged as the go-to vector for the central nervous system because it can cross the blood-brain barrier to some degree after intravenous injection. Still, delivering AAV through the spinal fluid rather than the bloodstream spreads the vector more broadly along the spinal cord with less off-target expression in other organs.16PubMed. Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery In non-human primates, intrathecal AAV9 delivery transduced neurons throughout the central nervous system while keeping peripheral expression low, an important safety consideration.17Molecular Therapy. AAV9 Vector Efficiently Crosses the Blood–Brain Barrier to Administer Gene Therapy and Reaches Central Nervous System Neurons in Nonhuman Primates
Researchers are also engineering entirely new AAV capsids, the protein shells that surround the viral vector, to cross the blood-brain barrier more efficiently. One team designed a capsid called BI-hTFR1 that hitchhikes on the human transferrin receptor, a protein naturally present on blood-brain barrier cells. In mice engineered to carry the human version of this receptor, BI-hTFR1 delivered 40 to 50 times more gene expression in the brain than standard AAV9.18PubMed Central. An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery Other groups have engineered capsids that interact with different barrier proteins in mice, though translating these to humans requires additional steps because the mouse and human blood-brain barriers differ in important ways.19PubMed Central. Targeting AAV vectors to the central nervous system by engineering capsid-receptor interactions that enable crossing of the blood-brain barrier
A completely different delivery strategy uses lipid nanoparticles, tiny fat-based particles, combined with focused ultrasound to temporarily open the blood-brain barrier. In one study, tofersen-loaded nanoparticles delivered intravenously and paired with transcranial focused ultrasound reduced SOD1 expression in the targeted brain regions and increased motor neuron survival in the spinal cords of treated mice, with the barrier opening proving safe and temporary.8PubMed Central. CRISPR/Cas9 a genomic engineering technology for treatment in ALS mouse models If this or similar non-viral approaches pan out, they could dramatically reduce the invasiveness of treatment.
Approaches That Do Not Require a Specific Mutation
One of the frustrations of mutation-targeted gene therapy is that most ALS patients do not carry an identified genetic mutation, or carry one for which no therapy yet exists. A parallel line of research uses gene therapy not to silence a bad gene, but to deliver protective proteins that support motor neuron survival regardless of the underlying cause.
GDNF, or glial cell line-derived neurotrophic factor, is a growth factor that helps keep motor neurons alive. In mouse models of SOD1-linked ALS, delivering the GDNF gene to muscles using a viral vector delayed symptom onset by about a week, extended survival by more than two weeks, and slowed the decline in motor function.20PubMed. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy A later study using human stem cells engineered to produce GDNF found that delivering them directly into muscle significantly reduced the loss of nerve-muscle connections.21PubMed Central. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS These neuroprotective strategies have the appeal of being potentially useful for all forms of ALS, though they remain in preclinical stages and the effects in animal models have been modest compared to what patients need.
Another approach combines gene silencing with immune modulation. In ALS, the brain’s resident immune cells, called microglia, often shift into an overactive inflammatory state that accelerates motor neuron death. One research group paired SOD1 silencing with delivery of galectin-1, a protein that calms microglial inflammation. In SOD1-mutant mice, the combination extended survival significantly more than SOD1 silencing alone, suggesting that targeting both the toxic protein and the inflammatory response together may be more effective than either strategy by itself.22Molecular Therapy. AAV9-mediated delivery of galectin-1 in combination with SOD1 silencing synergistically extends survival in a mouse model of amyotrophic lateral sclerosis
Safety Challenges and the Immune System
Gene therapy for ALS faces the same safety hurdle that gene therapy faces everywhere: the immune system does not always cooperate. AAV vectors, even though they are designed not to replicate, are still recognized by the body as foreign. The immune response can involve both an immediate inflammatory reaction and a longer-term adaptive response directed against the viral capsid and the protein the vector is delivering.23PubMed Central. Immune Toxicities in AAV Gene Therapy: Overview for Clinicians In other gene therapy fields, this has caused liver inflammation, drops in platelet counts, and in rare cases serious organ damage.
Pre-existing immunity adds another layer of difficulty. Many people have been naturally exposed to adeno-associated viruses during their lives and already carry antibodies against them. Those antibodies can neutralize a therapeutic AAV vector before it reaches its target cells, potentially rendering the treatment useless. This is one reason why intrathecal delivery, injecting directly into the spinal fluid, is attractive: it partially bypasses the circulating antibodies in the bloodstream. Reducing the total viral dose also lowers the risk of triggering a strong immune reaction.17Molecular Therapy. AAV9 Vector Efficiently Crosses the Blood–Brain Barrier to Administer Gene Therapy and Reaches Central Nervous System Neurons in Nonhuman Primates
ASOs like tofersen have a somewhat different safety profile. Because they are synthetic molecules rather than viruses, they do not provoke the same type of adaptive immune response. However, they can cause inflammation at the injection site, protein elevations in the spinal fluid, and in some patients, more serious neurological side effects. Clinical data on tofersen describe the drug as having an acceptable tolerability profile overall, though long-term monitoring continues.24PubMed. Tofersen: A Review in Amyotrophic Lateral Sclerosis Associated with SOD1 Mutations
The Role of Biomarkers in Measuring Success
Tofersen’s approval raised a question that will shape ALS gene therapy for years: how do you measure whether a treatment is working when the disease is variable and the trials are small? ALS progresses at very different rates in different people, which makes functional scales noisy. A drug might genuinely slow the disease but still fail to show a statistically clear benefit in a 28-week trial if the patient groups happen to include people with very fast or very slow progression.
Neurofilament light chain has stepped into this gap as a pharmacodynamic biomarker. When motor neurons are injured, they release NfL into the spinal fluid and blood. A treatment that reduces NfL levels is plausibly reducing nerve damage. NfL has already proven its worth as a biomarker in other neurological diseases, and its use in ALS is backed by a strong rationale: less nerve damage should mean lower NfL.25Brain. Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal Tofersen’s clear reduction in NfL was central to its FDA approval and set a precedent that future ALS gene therapies will likely follow.
The tension, though, is that a biomarker is not the same as a clinical outcome. Lowering NfL is encouraging, but patients and their families want to know whether they will breathe longer, move longer, live longer. The longer-term tofersen data showing slower functional decline in the early-start group are reassuring on this front, but the field is still working to establish exactly how much NfL reduction translates into how much clinical benefit.26Journal of Neurology, Neurosurgery & Psychiatry. Tofersen in adults with SOD1-ALS: phase 3 VALOR trial and open-label extension results Future trials for C9orf72 and FUS therapies will grapple with the same question.
Why Early Treatment and Genetic Testing May Change the Landscape
A recurring theme across the tofersen data is that earlier treatment appears to produce better outcomes. This makes biological sense: gene-silencing therapies can slow or halt the production of a toxic protein, but they cannot rebuild motor neurons that have already died. By the time most ALS patients are diagnosed, significant nerve loss has already occurred, which limits how much any therapy can recover.
This creates pressure to identify at-risk individuals before symptoms appear. Presymptomatic genetic testing of family members is becoming more common now that treatments like tofersen exist. If you carry an SOD1 mutation and monitoring shows early biomarker changes, starting therapy before clinical symptoms emerge could be far more effective than waiting for weakness or breathing problems. A similar logic would apply once C9orf72 and FUS therapies reach approval. The challenge is ethical and psychological: genetic testing for an incurable, fatal disease carries enormous emotional weight, and the decision to test or not test remains deeply personal, even with treatments becoming available.
The broader shift underway is that ALS is moving from a diagnosis that offers little beyond symptom management to one where genetic subtyping can guide meaningful treatment decisions. ASOs targeting SOD1, C9orf72, FUS, and ATXN2 are all in clinical trials.14PubMed Central. Antisense Oligonucleotides for the Study and Treatment of ALS Non-viral delivery platforms are being developed that could make treatment less invasive.8PubMed Central. CRISPR/Cas9 a genomic engineering technology for treatment in ALS mouse models And combination strategies that pair gene silencing with neuroprotection or immune modulation are beginning to show synergistic effects in animal models. None of this means a cure is imminent, but for a disease that went decades with essentially no disease-modifying therapy, the pace of progress is real.